Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Pulte, Dianne ^a,b   Barnes, Benjamin ^c   Jansen, Lina ^a   Eisemann, Nora ^d   Emrich, Katharina ^e   Gondos, Adam ^a   Hentschel, Stefan ^f   Holleczek, Bernd ^g   Kraywinkel, Klaus ^c   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c ROBERT KOCH INSTITUTE   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Authority for Social Affairs Family Health and Consumer Protection   (Germany)

^g SAARLAND CANCER REGISTRY   (Germany)

Author keywords

Chronic myeloid leukemia; Period analysis; Prognosis; Survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; DATA BASE; FEMALE; GERMANY; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; UNITED STATES;

ADOLESCENT; AGED; FEMALE; GERMANY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84883769585     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-70     Document Type: Article

References (39)

1. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Meyskens FL Jr, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H, Leuk Res 1995 19 9 605 612 10.1016/0145-2126(95)00032-J 7564470
2. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Hehlmann R, Heimpel H, Hasford J, et al. Blood 1993 82 2 398 407 8329700 (Pubitemid 23206102)
3. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Pulte D, Gondos A, Redaniel MT, Brenner H, Oncologist 2011 16 5 663 671 10.1634/theoncologist.2010-0393 21471276
4. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Hehlmann R, Heimpel H, Hasford J, et al. Blood 1994 84 12 4064 4077 7994025 (Pubitemid 24371908)
5. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. Guilhot F, Chastang C, Michallet M, et al. N Engl J Med 1997 337 4 223 229 10.1056/NEJM199707243370402 9227927 (Pubitemid 27310437)
6. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Clift RA, Bucknew CD, Thomas ED, et al. Blood 1994 84 6 2036 2043 8081005 (Pubitemid 24286157)
7. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Gale RP, Hehlmann R, Zhang MJ, et al. Blood 1998 91 5 1810 1819 9473250 (Pubitemid 28110349)
8. Lessons learned from the development of an abl tyrosine kinase inhitior for chronic myelogenous leukemia. Druker BJ, Lydon NB, J Clin Invest 2000 105 1 3 7 10.1172/JCI9083 10619854 (Pubitemid 30036380)
9. European public assessment report (EPAR) Glivec: EPAR summary for the public. European Medicines Agency (EMEA), EMEA/H/C 2009 406 3
10. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Cohen MH, Williams G, Johnson JR, et al. Clin Cancer Res 2002 8 935 942 12006504 (Pubitemid 34520420)
11. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Druker BJ, Guilhot F, O'Brien SG, et al. N Engl J Med 2006 355 23 2408 2417 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
12. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Hochhaus A, O'Brien SG, Guilhot F, et al. Leukemia 2009 23 6 1054 1061 10.1038/leu.2009.38 19282833
13. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Kantarjian HM, Shah NP, Cortes JE, et al. Blood 2012 119 5 1123 1129 10.1182/blood-2011-08-376087 22160483
14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM, Hochhaus A, Saglio G, et al. Lancet Oncol 2011 12 9 841 851 10.1016/S1470-2045(11)70201-7 21856226
15. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Brenner H, Gondos A, Pulte D, Haematologica 2008 93 10 1544 1549 10.3324/haematol.13045 18641022
16. Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Brenner H, Gondos A, Pulte D, Leuk Res 2009 33 12 1604 1608 10.1016/j.leukres.2009.01.042 19272642
17. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Wiggins CL, Harlan LC, Nelson HE, et al. M J Med 2010 123 8 1 9 764.e
18. Chronic myeloid leukemia in health regions 1,3,4, and 5 during the period 1990-96. Lamvik J, Brinch L, Dahl IM, et al. Tidsskr Nor Laegeforen 1999 119 12 1733 1736 10380587
19. Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Corm S, Roche L, Micol JB, et al. Blood 2011 118 16 4331 4337 10.1182/blood-2011-01-330332 21849485
20. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. Björkholm M, Ohm L, Eloranta S, et al. J Clin Oncol 2011 29 18 2514 2520 10.1200/JCO.2011.34.7146 21576640
21. Survival from common and rare cancers in Germany in the early 21§ssup§st§esup§ century. Hiripi E, Gondos A, Emrich K, et al. Ann Oncol 2012 23 2 472 479 10.1093/annonc/mdr131 21597096
22. Surveillance, Epidemiology, and End Results (SEER), Program (www.seer.cancer.gov) Research Data (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission
23. Projecting SEER cancer survival rates to the US: an ecological regression approach. Mariotto A, Capocaccia R, Verdecchia A, et al. Cancer Causes Control 2002 13 101 111 10.1023/A:1014380323037 11936816 (Pubitemid 34229675)
24. Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. Brenner H, Gefeller O, Hakulinen T, Eur J Cancer 2004 40 326 335 10.1016/j.ejca.2003.10.013 14746849 (Pubitemid 38121268)
25. An alternative approach to monitoring cancer patient survival. Brenner H, Gefeller O, Cancer 1996 78 9 2004 2010 10.1002/(SICI)1097-0142(19961101)78: 9<2004::AID-CNCR23>3.0.CO;2-# 8909323 (Pubitemid 26360586)
26. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Brenner H, Soederman B, Hakulinen T, Int J Epidemiol 2002 31 2 456 462 10.1093/ije/31.2.456 11980816 (Pubitemid 34537812)
27. Up-to-date long-term survival curves of patients with cancer by period analysis. Brenner H, Hakulinen T, J Clin Oncol 2002 20 3 826 832 10.1200/JCO.20.3.826 11821467 (Pubitemid 34111392)
28. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Sokel JE, Baccarni M, Tura S, et al. Blood 1985 66 6 1352 1357 3904870 (Pubitemid 16194698)
29. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Brenner H, Hakulinen T, Am J Epidemiol 2006 164 7 689 696 10.1093/aje/kwj243 16840519 (Pubitemid 44453498)
30. Ederer F, HH. Instructions to IBM 650 programmers in processing survival computations Bethesda, MD: National Cancer Institute 1959
31. United States life tables, 2000. Arias E, Natl Vit Stat Rep 2002 1 39
32. A computer program for period analysis of cancer patients survival. Brenner H, Gefeller O, Hakulinen T, Eur J Cancer 2002 38 690 695 10.1016/S0959-8049(02)00003-5 11916552 (Pubitemid 34251393)
33. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cortes J, Talpaz M, O'Brien S, et al. Cancer 2003 98 6 1105 1113 10.1002/cncr.11629 12973833 (Pubitemid 37099894)
34. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Gugliotta G, Castagnetti F, Palandri F, et al. Blood 2011 117 21 5591 5599 10.1182/blood-2010-12-324228 21450900
35. A global comparison regarding patient access to cancer drugs. Joensson B, Wilking N, Ann Oncol 2007 18 Suppl 3 ii1 iii77 17494969
36. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarni M, Lokey L, Cancer 2007 109 7 1365 1375 10.1002/cncr.22523 17326047 (Pubitemid 46466564)
37. Basic issues in estimating and comparing the survival of cancer patients. Berrino F, Esteve J, Coleman MP, IARC Sci Publ 1995 132 1 14 7797291
38. Interpreting international comparisons of cancer survival: the effects of incomplete registration and the presence of death certificate only cases on survival estimates. Robinson D, Sankila R, Hakulinen T, Moller H, Eur J Cancer 2007 43 5 909 913 10.1016/j.ejca.2007.01.007 17300929 (Pubitemid 46389484)
39. Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificate only. Brenner H, Holleczek B, Cancer Epidemiol Biomarkers Prev 2011 20 12 2480 2486 10.1158/1055-9965.EPI-11-0697 21960691